In this issue:
ctDNA profiling prognostic for survival in NSCLC
Adding cemiplimab to chemotherapy prolongs survival in NSCLC
A radiomics-based tool improves lung cancer diagnosis in large nodules
Model predicts response to neoadjuvant chemoimmunotherapy in NSCLC
Older adults with cancer in the US rarely participate in clinical trials
Incidental sinoatrial node irradiation associated with AF risk in lung cancer
Biomarkers for response to pembrolizumab monotherapy in low PD-L1 NSCLC
Adjuvant erlotinib prolongs survival vs chemo in resectable EGFR+ NSCLC
Subset of NSCLC patients mount a poor antibody response to COVID vaccination
Quality of life better with cemiplimab vs chemotherapy in NSCLC
Please login below to download this issue (PDF)